PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies.
Three different platforms; DELFIA®, DELFIA® Xpress and AutoDELFIA®, offer you optimal throughput for your specific needs for fetal and maternal screening. PerkinElmer’s complete solution enables pre-eclampsia risk assessment in all trimesters of pregnancy and provides a complete set of markers needed for Downs syndrome screening in both 1st and 2nd trimesters of pregnancy. Read more about pre-eclampsia screening here.
PerkinElmer has recently acquired Vanadis Diagnostics, which is developing a novel non-sequencing, non-PCR based solution for cfDNA analysis. In the future this acquisition will able PerkinElmer to offer a simplified, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.
Maternal fetal products availability and claims may differ from country to county based on regulations and product approvals. Please check availability with your local distributor.
AutoDELFIA® immunoassay system for prenatal screening is supported by the widest available range of prenatal analytes available on any platform. Reliable and easy to use AutoDELFIA instrument offers high quality results both for aneuploidy and pre-eclampsia risk assessment during pregnancy.
The VICTOR2™ D fluorometer is designed for all PerkinElmer diagnostic and screening assays based on either time-resolved fluorescence or prompt fluorescence. VICTOR2 D includes MultiCalc software for assay evaluation and quality control.
The DELFIA® and AutoDELFIA™ hAFP/Free hCGß Dual kits are for the simultaneous quantitative determination of human Alpha-fetoprotein (hAFP) and the free beta subunit of human Chorionic Gonadotrophin (Free hCGß) in maternal serum.